Determination of N-methyl-4-isoleucine-cyclosporin (NIM811) in human whole blood by high performance liquid chromatography-tandem mass spectrometry

Biomedical Chromatography

Volumn 21, Issue 3, 2007, Pages 249-256

  Li, Wenkui ^a   Luo, Suyi ^a   Hayes, Michael ^a   He, Handan ^a   Tse, Francis L S ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

LC MS MS; N methyl 4 isoleucine cyclosporin (NIM811)

Indexed keywords

AMINO ACIDS; BLOOD; CHROMATOGRAPHIC ANALYSIS; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PARTICLE SIZE;

CHROMATOGRAPHIC METHODS; CONCENTRATION RANGES; CYCLOSPORIN; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; INTERNAL STANDARDS; LC-MS-MS; LC.MS/MS; N-METHYL-4-ISOLEUCINE-CYCLOSPORIN (NIM811); TANDEM MASS SPECTROMETRIC DETECTION; WHOLE BLOOD;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ACETONITRILE; AMMONIUM ACETATE; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; N METHYL 4 ISOLEUCINE CYCLOSPORIN; NIM 811; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CONTROLLED STUDY; DILUTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXPOSURE; DRUG ISOLATION; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID LIQUID EXTRACTION; NORMAL HUMAN; QUALITY CONTROL; REPRODUCIBILITY; SENSITIVITY ANALYSIS; SEPARATION TECHNIQUE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 33947584118     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.746     Document Type: Article

References (16)

1. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D and Ovize M. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. Journal of Molecular and Cellular Cardiology 2005a; 38: 367-374.
2. Argaud L, Gateau-Roescb O, Raisky O, Loufouat J, Robert D and Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005b; 111(2): 194-197.
3. Billich A, Hammerschmid F, Peichl P, Wenger R, Zenke G, Quesniaux V and Rosenwirth B. Mode of action of SDZ NIM811, a nonimmunosuppressive cyclosporin A analog with active against human immunodeficiency virus type 1 (HIV-1): interference with HIV protein-cyclophilin A interactions. Journal of Virology 1995; 69(4): 2451-2461.
4. Bouchard MJ, Puro RJ, Wang L and Schneider RJ. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. Journal of Virology 2003; 77(14): 7713-7719.
5. Brignol N, McMahon LM, Luo S and Tse FLS. High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD001) and cyclosporine A (CsA) in whole blood. Rapid Communications in Mass Spectrometry 2001; 15: 898-907.
6. Dorfman T and Göttlinger HG. The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM811. Journal of Virology 1996; 70(9): 5751-5757.
7. Gomez L, Raisky O, Chalabrysse L, Verschelde C, Bonnefoy-Berard N and Ovize M. Link between immune cell infiltration and mitochondrial-induced cardiomyocyte death during acute cardiac graft rejection. American Journal of Transplantation 2006; 6(3): 487-495.
8. Hansson MJ, Mattiasson G, Månsson R, Karlsson J, Keep MF, Waldmeier P, Ruegg UT, Dumont JM, Besseghir K and Elmèr E. The nonimmunosuppressive cyclosporine analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. Journal of Bioenergetics and Biomembranes 2004; 36(4): 407-413.
9. Lin K, Ma S, Boerner J, Huang M, Ryder N, Weidmann B and Cooreman MP. NIM811 exhibits potent anti-HCV activity in vitro and represents a novel approach for viral hepatitis C therapy. American Association for the Study of Liver Diseases Annual Meeting, 11-15 November, 2005, San Francisco, CA.
10. McMahon LM, Luo S, Hayes M and Tse FL. High-throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semiautomated 96-well solid-phase extraction system. Rapid Communications in Mass Spectrometry 2000; 14: 1965-1971.
11. Mlynar E, Bevec D, Billich A, Rosenwirth B and Steinkasserer A. The non-immunosuppresseive cyclosporine A analogue SDZ NIM811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells. Journal of General Virology 1997; 78(4): 825-835.
12. Raisky O, Gomez L, Chalabreysse L, Gateau-Roesch O, Loufouat J, Thivolet-Bèjui F, Ninet J and Ovize M. Mitochondrial permeability transition in cardiomyocyte apoptosis during acute graft rejection. American Journal of Transplantation 2004; 4: 1071-1078.
13. Rosenwirth B, Billich A, Datema R, Donatsch P, Hammerschmid F, Harrison R, Hiestand P, Jaksche H, Mayer P, Peichi P, Quesniaux V, Schatz F, Schuurman HJ, Traber R, Wenger R, Wolff B, Zenke G and Zurini M. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM811, a nonimmunosuppressive cyclosporine analog. Antimicrobial Agents and Chemotherapy 1994; 38(8): 1763-1772.
14. Steinkasserer A, Harrison R, Billich A, Hammerschmid F, Werner G, Wolff B, Peichl P, Palfi G, Schnitzel W, Mlynar E and Rosenwirth R. Mode of action of SDZ NIM811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication. Journal of Virology 1995; 69(2): 814-824.
15. Thali M, Bukovsky A, Kondo E, Rosenwirth B, Walsh CT, Sodroski J and Göttlinger HG. Functional association of cyclosporine A with HIV-1 virus. Nature 1994; 372: 319-320.
16. Waldmeier PC, Feldtrauer JJ, Qian T and Lemasters JJ. Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811. Molecular Pharmacology 2002; 62(1): 22-29.